Abstract 20P
Background
In China, new breast cancer (BC) patients (pts) in county regions (including rural areas) account for more than 40% of all BC cases each year. No studies have reported the disease characteristics and treatment patterns of BC pts in China counties. This study aimed to explore the treatment patterns of BC pts in county-level hospitals in China.
Methods
CHASE001 was an observational, multicenter study assessing real-world treatment patterns among pts with HER2+ or HR+/HER2- BC conducted at 26 sites in county areas of China, including four cohorts (HER2+ early BC (eBC), HR+/HER2- eBC, HER2+ advanced BC (aBC), and HR+/HER2- aBC). The primary endpoint was treatment patterns within each cohort. The interim results for HER2+ eBC and HR+/HER2- eBC are described here.
Results
628 pts were included (302 in HER2+ eBC and 326 in HR+/HER2- eBC cohort): for HER2+ and HR+/HER2- cohort respectively, median age, 53/51 years; clinical T2, 41.39%/37.73%; clinical N0, 41.72%/45.40%. Of 584 pts who underwent breast cancer surgery, only 10.53% (30/285) received breast-conserving surgery (BCS) in HER2+ and 12.71% (38/299) in HR+/HER2- cohort. Notably, the proportions of adjuvant radiotherapy (RT) following BCS were 46.67% (14/30) in HER2+ and 47.37% (18/38) in HR+/HER2- cohort. In HER2+ cohort, 20.20% (61/302) received neoadjuvant therapy (NAT) while 94.70% (286/302) received adjuvant therapy. 81.97% (50/61) of NAT were HER2 targeted regimens, of which 84.00% (42/50) received dual anti-HER2 target therapy (trastuzumab/pertuzumab). 80.77% (231/286) of adjuvant therapies were HER2 targeted regimens, of which 53.68% (124/231) were dual-targeted. Of pts with positive lymph nodes who received HER2 targeted adjuvant therapy, 75.90% applied dual anti-HER2 target therapy. In HR+/HER2- cohort, 13.50% (44/326) received NAT while 92.02% (300/326) received adjuvant therapy. The most common neoadjuvant and adjuvant chemotherapy regimens were both AC-T (41.67% and 51.79%, respectively).
Conclusions
This analysis showed unsatisfactory adherence to guidelines for BCS, RT, and NAT, but higher adherence for adjuvant anti-HER2 therapy. Further action was needed to ensure that patients in Chinese county had access to high quality and guideline centric care.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract